Skip to main content
Madhav Thambisetty, MD, Neurology, Baltimore, MD

MadhavThambisettyMDPhD

Neurology Baltimore, MD

Dementia & Geriatrics

Investigator and Chief, Unit of Clinical and Translational Neuroscience, National Institute on Aging, National Institutes of Health. Adjunct Associate Professor of Neurology, Johns Hopkins University School of Medicine

Dr. Thambisetty is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Thambisetty's full profile

Already have an account?

Education & Training

  • Emory University School of Medicine
    Emory University School of MedicineFellowship, Cognitive Neurology and Sleep Disorders, 2002 - 2004
  • Emory University School of Medicine
    Emory University School of MedicineResidency, Neurology, 1999 - 2002
  • Emory University School of Medicine
    Emory University School of MedicineInternship, Internal Medicine, 1998 - 1999
  • University of Oxford
    University of OxfordPhD, Felix scholarship, 1995 - 1998
  • Calicut Medical College
    Calicut Medical CollegeClass of 1995

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2008 - 2025
  • GA State Medical License
    GA State Medical License 2002 - 2011
  • American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

  • Director's Merit Award National Institute on Aging, 2014
  • Director’s Merit Award National Institute on Aging, 2011
  • On-the-Spot award for outstanding accomplishment in scientific research National Institute on Aging, 2010
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease.  
    Whiley L, Sen A, Heaton J et al., NEUROBIOLOGY OF AGING 35(2):271-8, 2014
  • Pharmacologic inhibition of ROCK2 suppresses amyloid-ß production in an Alzheimer disease mouse model  
    Herskowitz JH, Feng, Higginbotham L et al., J NEUROSCIENCE 33(49):19086-98, 2013
  • Abnormal gephyrin immunoreactivity associated with Alzheimer disease pathologic changes.  
    Hales CM, Rees H, Seyfried NT et al., J NEUROPATHOL EXP NEUROL 72(11):1009-15, 2013
  • Join now to see all

Abstracts/Posters

  • Impaired glucose tolerance predicts longitudinal changes in brain function during aging in non- demented elderly
    Thambisetty M, Beason-Held L, An Y et al, 15th International Conference on Alzheimer’s Disease and Related Disorders, Vancouver, Canada, 1/1/2012
  • The Effect of CR1 on Brain Amyloid Burden during Aging and its Modification by APOE Genotype
    Thambisetty M, An Yang, Nalls M et al, 6th Human Amyloid Imaging meeting, Miami, FL, 1/1/2012
  • Alzheimer’s risk variant clusterin (CLU) and brain function in aging
    Thambisetty M, Beason-Held L, Kraut M et al, 14th International Conference on Alzheimer’s Disease and Related Disorders, Paris, 1/1/2011
  • Join now to see all

Lectures

  • APOE and partners in the post GWAS era: discovering biomarkers and understanding mechanisms in Alzheimer’s Disease 
    6/1/2013
  • Is it memory loss or Alzheimer’s disease? Know the facts 
    5/1/2012
  • Neuroimaging and Genetic Findings in Alzheimer’s Disease from the Baltimore Longitudinal Study of Aging 
    11/1/2011
  • Join now to see all

Authored Content

  • Manufacturers Need To Be More Open About a Dangerous Alzheimer’s Drug Side EffectNovember 2023
  • ‘When Memory Fades’: Misinformation About Alzheimer’s Disease and Aduhelm Must Be LimitedJuly 2021

Press Mentions

  • Why Are Makers of Alzheimer’s ‘Wonder Drug’ so Silent over Its Side Effects?
    Why Are Makers of Alzheimer’s ‘Wonder Drug’ so Silent over Its Side Effects?May 1st, 2023
  • Promising Alzheimer’s Therapy and Related Drugs Shrink Brains
    Promising Alzheimer’s Therapy and Related Drugs Shrink BrainsMarch 28th, 2023
  • The New Alzheimer’s Drug: All Your Questions, Answered
    The New Alzheimer’s Drug: All Your Questions, AnsweredJanuary 26th, 2023
  • Join now to see all

Committees

  • Member and keynote speaker, Peripheral and Central Nervous System Drugs Advisory Committee 2011 - 2011

Professional Memberships

  • American Neurological Association
    Member